



Antibodies

1B-214-C100

Monoclonal Antibody to CD16 Biotin conjugated (0.1 mg)

Clone:	MEM-154
Isotype:	Mouse IgG1
Specificity:	<p>The antibody MEM-154 reacts with an epitope on CD16 antigen that is residing in proximity to FG loop (probably BC or C'E loop). CD16 is a low affinity receptor for aggregated IgG (FcγRIII antigen). The antibody MEM-154 reacts with CD16+ granulocytes.</p> <p>HLDA V; WS Code M MA068 HLDA V; WS Code NK NK51</p>
Regulatory Status:	RUO
Immunogen:	Human granulocytes
Species Reactivity:	Human
Preparation:	The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions. The reagent is free of unconjugated biotin.
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Usage:	<p>Biotinylated antibody is designed for indirect immunofluorescence analysis by Flow Cytometry.</p> <p>Suggested working dilution is 1:500. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.</p>
Expiration:	See vial label
Lot Number:	See vial label
Background:	<p>CD16 (FcγRIII) is a 50-65 kDa glycoprotein serving as a low affinity IgG receptor. Human FcγRIII is expressed in two forms &#8211; FcγRIII-A and -B. FcγRIII-A is a transmembrane protein of monocytes, macrophages, NK cells and a subset of T cells. It is associated with FcεRI-gamma subunit and is responsible for antibody-dependent NK cell cytotoxicity. Mast cell FcγRIII-A is associated, moreover, with FcεRI-beta subunit. Besides IgG, FcγRIII-A can be triggered also by oligomeric IgE. FcγRIII-B is a GPI-linked monomeric receptor expressed on neutrophils and is involved in their activation and induction of a proadhesive phenotype.</p>

For laboratory research only, not for drug, diagnostic or other use.

**Antibodies****References:**

- *Gessner JE, Grussenmeyer T, Kolanus W, Schmidt RE: The human low affinity immunoglobulin G Fc receptor III-A and III-B genes. Molecular characterization of the promoter regions. *J Biol Chem.* 1995 Jan 20;270(3):1350-61.
- *Kocher M, Siegel ME, Edberg JC, Kimberly RP: Cross-linking of Fc gamma receptor IIa and Fc gamma receptor IIIb induces different proadhesive phenotypes on human neutrophils. *J Immunol.* 1997 Oct 15;159(8):3940-8.
- *Arase N, Arase H, Hirano S, Yokosuka T, Sakurai D, Saito T: IgE-mediated activation of NK cells through Fc gamma RIII. *J Immunol.* 2003 Mar 15;170(6):3054-8.
- *Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
- *de Haas M, Koene HR, Kleijer M, de Vries E, Simsek S, van Tol MJ, Roos D, von dem Borne AE: A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. *J Immunol.* 1996 Apr 15;156(8):3948-55.
- *Tamm A, Schmidt RE: The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. *J Immunol.* 1996 Aug 15;157(4):1576-81.
- *Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M: Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. *Blood.* 1997 Aug 1;90(3):1109-14.
- *Gasdaska JR, Sherwood S, Regan JT, Dickey LF: An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. *Mol Immunol.* 2012 Mar;50(3):134-41
- *Ohradanova-Repic A, Machacek C, Charvet C, Lager F, Le Roux D, Platzer R, Leksa V, Mitulovic G, Burkard TR, Zlabinger GJ, Fischer MB, Feuillet V, Renault G, Blüml S, Benko M, Suchanek M, Huppa JB, Matsuyama T, Cavaco-Paulo A, Bismuth G, Stockinger H: Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances. *Front Immunol.* 2018 Apr 27;9:852.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz